department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

ALUMIS INC. ($ALMS) · pharmadog

PUBLIC COMPANY

$ALMSALUMIS INC.

South San Francisco, CA, USupdated 1h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

1

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 21Phase 3

Plaque Psoriasis (Psoriasis Vulgaris)

Graves' Ophthalmopathy

Upcoming

no upcoming catalysts on record

Recent

🕒

(90d)

earnings (1)

ALUMIS INC. earnings

view all catalysts →

🐶 Hiring Signal

19 open roles at ALUMIS INC. →

Where ALUMIS INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaImmunology & Inflammation 19

departmentMedical Affairs 6 Commercial 4 R&D / Discovery 3 Finance 1 Market Access 1 Quality 1

News

no news has mentioned this company yet

identifiers

ticker

$ALMS

SEC CIK

0001847367

country

US

source

sec_tickers

top tags

Immunology1 Ophthalmology1

mentioned in

0news items

entity-linker matched

$ALMS27.27+2.91%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 11m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasiscompletedn=912
phase3Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasisactive not recruitingn=1,680
phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001completedn=862
phase2Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosusactive not recruitingn=408
phase2Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasisactive not recruitingn=165
phase1An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005completedn=135
phase1An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001completedn=52
phase1An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Functioncompletedn=16

more trials →

Insider activity

source: SEC Form 4

routine RSU / option mechanics (6)

Apr 1, 26otherForesite Labs, LLC · 1,176,470 sh
Apr 1, 26otherForesite Labs, LLC · 1,123,337 sh
Apr 1, 26otherForesite Labs, LLC · 1,123,337 sh
Apr 1, 26otherForesite Labs, LLC · 680,486 sh
Apr 1, 26otherForesite Capital Management VI LLC · 1,176,470 sh
Apr 1, 26otherForesite Capital Management VI LLC · 1,123,337 sh

$ALMS27.27+2.91%